Genentech, a unit of the Roche Group (RHHBY:PK) announced the results of study which showed the addition of Avastin to chemotherapy extended the lives of women with advanced cervical cancer, compared to chemotherapy alone.
The study met its primary endpoint of improving overall survival with a statistically significant 29 percent reduction in the risk of death for women who received Avastin plus chemotherapy compared to those who received chemotherapy alone.
The company noted that the women who received Avastin plus chemotherapy lived a median of 3.7 months longer compared to those who received chemotherapy alone and the median overall survival was 17.0 months with Avastin plus chemotherapy compared to 13.3 months for chemotherapy alone.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.